Ascendis Pharma A/S

NASDAQ: ASND · Real-Time Price · USD
197.97
5.93 (3.09%)
At close: Aug 15, 2025, 3:59 PM
200.00
1.03%
After-hours: Aug 15, 2025, 06:18 PM EDT

Ascendis Pharma A/S Income Statement

Financials in EUR. Fiscal year is January - December.
Fiscal Year Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
100.95M 173.92M 57.83M 36M 95.89M 137.7M 48.03M 47.39M 33.59M 22.9M 15.29M 6.16M 6.83M 4.9M 1.11M 1.02M 746K
Cost of Revenue
17.52M 14.02M 11.2M 11.46M 7.57M 19.46M 7.39M 12.93M 4.62M 5.11M 1.69M 1.09M 4.25M 3.52M n/a n/a n/a
Gross Profit
83.44M 159.89M 46.63M 24.53M 88.33M 118.25M 40.65M 34.46M 28.97M 17.78M 13.6M 5.07M 2.58M 1.37M 1.11M 1.02M 746K
Operating Income
-104.21M 383K -96.74M -133.26M -49.15M -36.61M -134.41M -140.84M -143.69M -147.39M -144.5M -141.89M -128.03M -112.58M -96.93M -117.63M -124.65M
Interest Income
28.85M -66.55M 28.28M 49.05M 3.58M n/a 4.14M 35.76M 45.13M n/a 20.33M 71.13M 13.04M n/a 21.32M 145K 34.43M
Pretax Income
-93.56M -37.38M -98.18M -109.15M -128.53M -81.09M -161.58M -121.86M -109.62M -202.07M -169.12M -81.37M -125.26M -106.18M -80.34M -134.44M -62.98M
Net Income
-94.63M -38.47M -99.2M -109.38M -131.03M -86.88M -162.22M -121.43M -110.91M -207.42M -168.96M -81.32M -125.5M -106.06M -80.35M -134.37M -62.79M
Selling & General & Admin
101.05M 78.78M 68.13M 74.31M 66.78M 63.98M 63.61M 70.28M 66.54M 56.55M 60.67M 56.58M 47.42M 48.3M 39.28M 35.34M 37.25M
Research & Development
86.6M 79.3M 73.54M 83.48M 70.69M 90.88M 111.44M 105.02M 106.11M 108.62M 97.43M 90.38M 83.19M 65.65M 58.76M 83.31M 88.15M
Other Expenses
n/a 1.43M 1.7M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 0.00
Operating Expenses
187.65M 159.51M 143.38M 157.79M 137.47M 154.86M 175.05M 175.3M 172.65M 165.17M 158.1M 146.97M 130.61M 113.95M 98.05M 118.65M 125.4M
Interest Expense
44.79M -56.63M 25.35M 19.62M 77.16M 68.55M 24.52M 9.33M 9.84M 71.67M 41.25M 9.43M 5.4M 45.23M 877K 12.14M 869K
Selling & Marketing Expenses
n/a n/a n/a 2.02M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
205.17M 173.53M 154.58M 169.25M 145.04M 174.31M 182.44M 188.23M 177.27M 170.28M 159.79M 148.05M 134.86M 117.48M 98.05M 118.65M 125.4M
Income Tax Expense
1.06M 1.08M 1.02M 229K 2.51M 5.79M 645K -429K 1.3M 5.35M -167K -47K 241K -114K 5K -68K -191K
Shares Outstanding (Basic)
60.02M 59.79M 58.57M 57.35M 56.88M 56.61M 56.27M 56.22M 56.09M 55.99M 55.83M 55.81M 56.72M 53.85M 54.64M 53.85M 53.76M
Shares Outstanding (Diluted)
60.02M 59.79M 58.57M 57.35M 56.88M 56.61M 56.27M 56.22M 56.09M 55.99M 55.83M 55.81M 56.72M 53.85M 54.64M 53.85M 53.76M
EPS (Basic)
-1.58 -0.64 -1.69 -1.91 -2.3 -1.53 -2.88 -2.16 -1.98 -3.7 -3.03 -1.46 -2.21 -1.97 -1.47 -2.5 -1.17
EPS (Diluted)
-1.58 -0.64 -1.69 -1.91 -2.3 -1.53 -2.88 -2.16 -1.98 -3.7 -3.03 -1.46 -2.21 -1.97 -1.47 -2.5 -1.17
EBITDA
-48.78M -37.89M -71.13M -87.51M -46.89M -67.69M -132.32M -107.88M -103.28M -145.94M -139.99M -137.5M -115.44M -100.57M -75.68M -118.68M -58.4M
EBIT
-48.78M -42.37M -72.83M -89.53M -51.37M -72.66M -137.06M -112.53M -107.83M -147.39M -144.5M -141.89M -119.86M -104.84M -79.47M -122.3M -62.11M
Depreciation & Amortization
n/a 4.47M 1.7M 2.02M 4.5M 4.85M 4.88M 4.63M 4.55M 1.44M 4.64M 4.46M 4.48M 4.3M 3.85M 3.68M 3.81M